ENDONOVO THERAPEUTICS, INC. ENDV
ENDONOVO THERAPEUTICS, INC. statistics & valuation
Market cap$180,756
P / S1.3×
Net margin-13649.2%
Net debt$7.2M
Enterprise value USD$7.3M
Earnings yield EBIT/EV-44.5%
Market cap as of 2026-07-04. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 92.6% | 79.5% | 60.6% | 69.9% | 84.5% | — | — | 49.3% | 36.0% | 38.9% |
| Operating margin | -2411.7% | -3045.7% | -1756.5% | -1228.1% | -4995.3% | — | — | -60132.7% | -9057.6% | -10607.6% |
| Net margin | -13649.2% | -4247.2% | -238.6% | -5582.4% | -7729.5% | — | — | -158633.9% | -3966.2% | -12634.5% |
| FCF margin | — | — | — | -820.1% | -3468.3% | — | — | -23989.8% | -3758.7% | — |
| Return on assets | -1441.9% | -154.7% | -15.2% | -528.7% | -151.7% | -234.4% | -1668.0% | -1652.7% | -2104.7% | -3930.8% |
| Return on equity | 57.4% | 19.7% | 2.8% | 84.4% | 56.5% | 113.2% | 62.1% | 72.9% | 20.4% | 70.0% |
| Debt / equity | -0.22× | -0.46× | -0.48× | -0.34× | -0.72× | -0.77× | -0.37× | -0.00× | -0.34× | — |
| Current ratio | 0.00 | 0.01 | 0.00 | 0.00 | 0.02 | 0.01 | 0.03 | 0.04 | 0.00 | 0.00 |
Computed from company filings · US · as of 2022-12-31. Facts plus Stocktoria's own computed scores — not investment advice.